Remedy Gel, hydrocortisone 1%, 30 mL/ 1 fl oz per bottle, Distributed By: glo Skin Beauty, Denver, CO 80216. NDC 66915-531-12; 66915-531-13
Island Kinetics, Inc. d.b.a. CoValence Laboratories
Subpotent Drug
95,018 total recalls in our database
Island Kinetics, Inc. d.b.a. CoValence Laboratories
Subpotent Drug
PAYLESS COMPOUNDERS
Lack of Assurance of Sterility
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.
International Medication Systems
Lack of Assurance of Sterility
Owen Biosciences
Chemical contamination: Presence of benzene
Island Kinetics, Inc. d.b.a. CoValence Laboratories
Subpotent Drug
SUN PHARMACEUTICAL INDUSTRIES
Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
Xiamen Kang Zhongyuan Biotechnology Co.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
Labelling: Illegible label
Xiamen Kang Zhongyuan Biotechnology Co.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
SUN PHARMACEUTICAL INDUSTRIES
Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.
Xiamen Kang Zhongyuan Biotechnology Co.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
The Harvard Drug Group
Failed Dissolution Specifications
Xiamen Kang Zhongyuan Biotechnology Co.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
Xiamen Kang Zhongyuan Biotechnology Co.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
Xiamen Kang Zhongyuan Biotechnology Co.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
Xiamen Kang Zhongyuan Biotechnology Co.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
Chemical contamination: Presence of benzene